Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02695121 · ClinicalTrials.gov registry record
Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment
A clinical trial of Breast Cancer and Bladder Cancer, sponsored by AstraZeneca.
- Completed
- Registry status
- 2,133,575
- Enrollment target
- 4
- Study locations
NCT02695121 is a study of Breast Cancer and Bladder Cancer that has completed, run by AstraZeneca. The registered enrollment target is 2,133,575 participants, above the 1,060-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (201181% higher). The trial reports 4 study locations across 3 states.
The verdict
NCT02695121, a study of Breast Cancer and Bladder Cancer, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 2,133,575 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objectives of this study are (1) to compare the incidence of breast cancer, by insulin use at cohort entry, among females with type 2 diabetes who are new users of dapagliflozin and females who are new users of antidiabetic drugs (ADs) in classes other than sodium-glucose cotransporter 2 (SGLT2) inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy and (2) to compare the incidence of bladder cancer, by insulin use at the index date and by pioglitazone use at the index date, among male and female patients with type 2 diabetes who are new users of dapagliflozin and those who are new users of ADs in classes other than SGLT2 inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy. Secondary objectives will compare, by insulin use at cohort entry, frequency of several measures of health care use, baseline characteristics, and incidence of selected other cancers in males and females between the two exposure cohorts.
Conditions Studied
Study Locations (4)
Other
- Research Site - Utrecht
- Research Site - London
Delaware
- Research Site - Wilmington
District of Columbia
- Research Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,133,575 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2025-01-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02695121
The ClinicalTrials.gov registry entry for NCT02695121 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,133,575 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,060-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (201181% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02695121 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Other, Delaware, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT02695121 about?
NCT02695121 is a clinical study titled "Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment". The primary objectives of this study are (1) to compare the incidence of breast cancer, by insulin use at cohort entry, among females with type 2 diabetes who are new users of dapagliflozin and females who are new users of antidiabetic drugs (ADs) in classes other than sodium-glucose cotransporter 2...
What is the current status of trial NCT02695121?
This trial is currently completed. The enrollment target is 2,133,575 participants. The study started on 2017-01-01. Estimated completion is 2025-01-30.
What conditions does trial NCT02695121 study?
This clinical trial studies the following conditions: Breast Cancer, Bladder Cancer.
Who is sponsoring clinical trial NCT02695121?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02695121 being conducted?
This trial has 4 study locations across Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.